ReviewMolecular cancer2009
From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.
Review in Molecular cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance.Journal of clinical medicine · 2022Article
- Differentially Expressed mRNAs and Their Long Noncoding RNA Regulatory Network withBioMed research international · 2020Article
- Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.Acta pharmaceutica Sinica. B · 2019Article
- Article
- Key elements involved in Epstein-Barr virus-associated gastric cancer and their network regulation.Cancer cell international · 2018Article
- Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.EBioMedicine · 2017Article
- Proteomics and peptidomics: moving toward precision medicine in urological malignancies.Oncotarget · 2016Review
- Web-based tools for microRNAs involved in human cancer.Oncology letters · 2016Article
- Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?Viszeralmedizin · 2015Review
- Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model.Archives of biochemistry and biophysics · 2015Article
- MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons.International journal of molecular sciences · 2014Review
- Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.Pathology oncology research : POR · 2014Article
- Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.British journal of cancer · 2014Article
- Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma.Oncotarget · 2014Article
- Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma.Frontiers in oncology · 2014Review
- Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.Radiology and oncology · 2013Review
- Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.PloS one · 2013Article
- Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance.Molecular & cellular proteomics : MCP · 2013Article
- RCDB: Renal Cancer Gene Database.BMC research notes · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the adult population, renal cell carcinoma (RCC) constitutes the most prevalent form of kidney neoplasm. Unfortunately, RCC is relatively asymptomatic and there are no tumor markers available for diagnostic, prognostic or predictive purposes. Molecular profiling, the global analysis of gene and protein expression profiles, is an emerging promising tool for new biomarker identification in RCC. In this review, we summarize the existing knowledge on RCC regarding clinical presentation, treatment options, and tumor marker status. We present a general overview of the more commonly used approaches for molecular profiling at the genomic, transcriptomic and proteomic levels. We also highlight the emerging role of molecular profiling as not only revolutionizing the process of new tumor marker discovery, but also for providing a better understanding of the pathogenesis of RCC that will pave the way towards new targeted therapy discovery. Furthermore, we discuss the spectrum of clinical applications of molecular profiling in RCC in the current literature. Finally, we highlight some of the potential challenging that faces the era of molecular profiling and its transition into clinical practice, and provide an insight about the future perspectives of molecular profiling in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.